tiprankstipranks
Advertisement
Advertisement

CANF Stock Latest News

Can-Fite BioPharma Showcases Broad Potential of A3AR Drug Platform in New Peer-Reviewed Study
Company AnnouncementsCan-Fite BioPharma Showcases Broad Potential of A3AR Drug Platform in New Peer-Reviewed Study
1d ago
6K
CANF
Can-Fite BioPharma to Showcase Late-Stage Pipeline and Licensing Deals at BIO 2026
PremiumCompany Announcements
Can-Fite BioPharma to Showcase Late-Stage Pipeline and Licensing Deals at BIO 2026
6d ago
6K
CANF
Can-Fite BioPharma Shareholders Approve All Proposals at 2026 Annual Meeting
PremiumCompany Announcements
Can-Fite BioPharma Shareholders Approve All Proposals at 2026 Annual Meeting
19d ago
6K
CANF
Can-Fite BioPharma Posts Positive Phase 2a Signal for Namodenoson in Pancreatic Cancer
PremiumCompany Announcements
Can-Fite BioPharma Posts Positive Phase 2a Signal for Namodenoson in Pancreatic Cancer
21d ago
6K
CANF
Can-Fite BioPharma Adjourns 2026 Shareholder Meeting for Lack of Quorum
PremiumCompany Announcements
Can-Fite BioPharma Adjourns 2026 Shareholder Meeting for Lack of Quorum
26d ago
6K
CANF
Can-Fite and Vetbiolix Gain Peer-Reviewed Validation for Piclidenoson in Canine Osteoarthritis
PremiumCompany AnnouncementsCan-Fite and Vetbiolix Gain Peer-Reviewed Validation for Piclidenoson in Canine Osteoarthritis
1M ago
6K
CANF
Can-Fite BioPharma upgraded to Buy from Hold at D. Boral Capital
Premium
The Fly
Can-Fite BioPharma upgraded to Buy from Hold at D. Boral Capital
1M ago
CANF
Can-Fite to Advance Namodenoson into Phase 2b Pancreatic Cancer Combo Trial After Positive Data
Premium
Company Announcements
Can-Fite to Advance Namodenoson into Phase 2b Pancreatic Cancer Combo Trial After Positive Data
1M ago
6K
CANF
Can-Fite BioPharma target adjusted to $5 from $2.50 at H.C. Wainwright
PremiumThe Fly
Can-Fite BioPharma target adjusted to $5 from $2.50 at H.C. Wainwright
1M ago
CANF
Can-Fite Posts Positive Phase 2a Results for Namodenoson in Advanced Pancreatic Cancer
PremiumCompany Announcements
Can-Fite Posts Positive Phase 2a Results for Namodenoson in Advanced Pancreatic Cancer
2M ago
6K
CANF
Can-Fite BioPharma Sets May 28, 2026 AGM to Vote on Share Capital Increase and Executive Option Grants
PremiumCompany Announcements
Can-Fite BioPharma Sets May 28, 2026 AGM to Vote on Share Capital Increase and Executive Option Grants
2M ago
6K
CANF
Can-Fite BioPharma files to sell 3.29M ordinary shares for holders
PremiumThe Fly
Can-Fite BioPharma files to sell 3.29M ordinary shares for holders
3M ago
CANF
Can-Fite and Vetbiolix Complete Phase 2 Enrollment for Canine Osteoarthritis Drug Piclidenoson
PremiumCompany AnnouncementsCan-Fite and Vetbiolix Complete Phase 2 Enrollment for Canine Osteoarthritis Drug Piclidenoson
3M ago
6K
CANF
Can-Fite BioPharma completes enrollment in Piclidenoson study
Premium
The Fly
Can-Fite BioPharma completes enrollment in Piclidenoson study
3M ago
CANF
Can-Fite BioPharma Posts 2025 Loss but Highlights Long-Term Cancer Survival and Clinical Progress
Premium
Company Announcements
Can-Fite BioPharma Posts 2025 Loss but Highlights Long-Term Cancer Survival and Clinical Progress
3M ago
6K
CANF
CANF Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
CANF Upcoming Earnings Report: What to Expect?
3M ago
CANF
Can-Fite Secures Israeli Patent to Bolster Namodenoson Anti-Obesity Franchise
PremiumCompany Announcements
Can-Fite Secures Israeli Patent to Bolster Namodenoson Anti-Obesity Franchise
3M ago
6K
CANF
Can-Fite BioPharma announces Israeli patent allowance for namodenoson
PremiumThe Fly
Can-Fite BioPharma announces Israeli patent allowance for namodenoson
3M ago
CANF
Can-Fite BioPharma Shareholders Approve All Proposals at March 10 Special Meeting
PremiumCompany Announcements
Can-Fite BioPharma Shareholders Approve All Proposals at March 10 Special Meeting
3M ago
6K
CANF
Can-Fite BioPharma Secures $4 Million via Repriced Warrant Exercise to Fund Clinical Pipeline
PremiumCompany AnnouncementsCan-Fite BioPharma Secures $4 Million via Repriced Warrant Exercise to Fund Clinical Pipeline
4M ago
6K
CANF
Can-Fite’s Namodenoson Clears Phase 2a Safety Bar in Advanced Pancreatic Cancer
Premium
Company Announcements
Can-Fite’s Namodenoson Clears Phase 2a Safety Bar in Advanced Pancreatic Cancer
4M ago
6K
CANF
Can-Fite BioPharma says namodenoson meets primary endpoint in Phase 2a study
Premium
The Fly
Can-Fite BioPharma says namodenoson meets primary endpoint in Phase 2a study
4M ago
CANF

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >